Value of monitoring circulating donor‐reactive memory B cells to characterize antibody‐mediated rejection after kidney transplantation. Issue 2 (17th September 2018)

• Record Type: Journal Article
• Authors: Luque, Sergi; Lúcia, Marc; Melilli, Edoardo; Lefaucheur, Carmen; Crespo, Marta; Loupy, Alex; Bernal‐Casas, David; Gomà, Montse; Jarque, Marta; Crespo, Elena; Montero, Núria; Manonelles, Anna; Cruzado, Josep M.; Gil‐Vernet, Salvador; Grinyó, Josep M.; Bestard, Oriol
• Is Part Of: American journal of transplantation. Volume 19:Issue 2(2019)
• Page Start: 368
• Page End: 380
• Publication Date: 2018-09-17
• Subjects: alloantibody -- biomarker -- clinical research/practice -- histocompatibility -- kidney transplantation/nephrology -- major histocompatibility complex (MHC) -- monitoring: immune -- pathology/histopathology -- rejection: antibody‐mediated (ABMR) -- translational research/science; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.15055
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Antibody‐mediated rejection (ABMR) is defined by specific histopathological lesions and evidence of circulating donor‐specific antibodies (DSA). Although DSA are not always detectable, monitoring donor‐reactive memory B cells (mBC) could identify patients at risk of developing ABMR. Peripheral donor‐reactive mBC using a novel HLA B cell ELISpot assay, serum DSA, and numbers of different B cell subsets were assessed in 175 consecutive kidney transplants undergoing either for‐cause or 6‐ and 24‐month surveillance biopsies for their association with main histological lesions of ABMR and impact on allograft outcome. In 85 incident for‐cause biopsies, high frequencies of donor‐reactive mBC were detected in all 16 (100%) acute ABMR/DSA+ and most chronic ABMR, with or without DSA (24/30[80%] and 21/29[72.4%], respectively). In a longitudinal cohort of 90 nonsensitized patients, a progressively higher expansion of donor‐reactive mBC than de novo DSA was observed at 6 and 24 months (8.8% vs 7.7% and 15.5% vs 11.1%, respectively) and accurately identified patients with ongoing subclinical ABMR (area under the curve = 0.917 and area under the curve = 0.809, respectively). An unsupervised hierarchical cluster analysis revealed a strong association between donor‐reactive mBC with main fundamental allograft lesions associated with ABMR and conferred a significant deleterious impact on graft outcome. Monitoring donor‐reactive mBC may be useful to further characterize humoral rejection after kidney transplantation. Abstract : This study suggests the potential of measuring donor‐reactive memory B cells to identify transplant patients at risk of antibody‐mediated rejection regardless of the presence of detectable circulating donor‐specific antibodies in the serum.